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Abstract We purified a soluble gp83 trans-sialidase (gp83-
TSA), from phospholipase C-treated Trypanosoma cruzi trypo-
mastigote membranes, which binds to myoblasts, fibroblasts and
macrophages to mediate trypanosome entry. Myoblasts display a
single class of receptors for the gp83-TSA present at 4U104 per
myoblast with a Kd of 8 nM. Monovalent Fab fragments of the
monoclonal antibody 4A4 specific for gp83-TSA inhibit gp83-
TSA binding to myoblasts, fibroblasts and macrophages, block
the trypanosomes from attaching to and entering these cells and
neutralize T. cruzi infection in BALB/c mice. This is the first
demonstration that gp83-TSA is a ligand that T. cruzi uses to
attach to cells. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Trypanosoma cruzi, the protozoon that causes Chagas’ dis-
ease a¡ecting millions of people, must bind to mammalian
cells before entry to establish infection [1]. Chagas’ disease
is acquired by binding and entry of invasive trypomastigotes,
which are transmitted by insect vectors, or by blood infected
with trypomastigotes during blood transfusion. This organism
is now viewed as an emerging human pathogen of HIV-1-
infected individuals, since it induces dramatic brain pathology
and earlier death when associated with HIV-1 infection [2].
Although molecules have been suggested to serve as parasite
ligands [3^6], direct evidence of their involvement or of their
host cell receptors in the binding process does not currently
exist. The identi¢cation of T. cruzi surface molecules that
function as ligands to mediate trypanosome attachment to
phagocytic and non-phagocytic cells may be critical to the
development of molecular means of intervention against this
organism.
The surface of invasive T. cruzi trypomastigotes is covered
primarily by a very large and diverse family of trans-sialidases
and mucin-like molecules, with yet unknown functions in try-
panosome^host cell interactions [7,8]. T. cruzi is unable to
synthesize sialic acid and acquires this molecule from the
host via surface trans-sialidases which transfer sialic acid
from host glycoproteins to mucin-like molecules located on
the surface of the trypanosome [7]. Current thoughts suggest
that trans-sialidases will do more than just transfer sialic acid
[7]. Because previous reports have shown that the T. cruzi
surface gp83 [9,10] is expressed only in invasive trypomasti-
gotes [11], is more expressed in highly than weakly infective
trypomastigote clones [3] and that blocking this molecule with
anti-gp83 antibodies reduces trypanosome binding and inva-
sion [11], we explored the possibility that the surface gp83 is a
T. cruzi ligand that binds to host cells in a ligand^receptor
interaction manner in order to facilitate trypanosome entry.
In this paper we provide the ¢rst direct evidence that
T. cruzi uses the surface gp83 trans-sialidase as a ligand to
bind receptors on myoblasts, ¢broblasts and macrophages to
mediate trypanosome attachment to these cells and initiate in
vitro and in vivo infection.
2. Materials and methods
2.1. Organism
The highly infective trypomastigote clone MMC 20A of the Tula-
huen strain of T. cruzi that highly expresses the surface gp83 was used
[3]. Pure culture trypomastigotes were obtained from the supernatant
of heart myoblast monolayers [12].
2.2. Monovalent Fab fragments
The mouse monoclonal antibody (mAb) 4A4 that recognizes the
surface gp83 of T. cruzi trypomastigotes [11] and inhibits trypano-
some binding to heart myoblasts [11] was used. mAb 4A4 and an
isotype control (I-mAb) were puri¢ed using a mannan binding column
(IgM puri¢cation kit, Pierce). Monovalent Fab fragments (Fab) were
obtained using an IgM fragmentation kit (Pierce). Digestion products
were separated on Superose gel ¢ltration (Pharmacia Biotechnology)
using FPLC [13]. Puri¢ed Fab showed only one band when analyzed
by SDS^PAGE and stained with silver stain or when analyzed by
immunoblots [14]. In this paper, Fab of mAb 4A4 are abbreviated
as 4A4-Fab and Fab of isotype control mAb are abbreviated I-Fab.
Fab of rabbit polyclonal antibodies to gp83 (P-Fab) and of pre-im-
mune serum (IP-Fab) were puri¢ed by isolating IgG using a protein G
column followed by a monovalent Fab IgG puri¢cation kit (Pierce)
and Superose gel ¢ltration as above. Immunoblots of gp83 probed
with Fab were developed by ECL [15].
2.3. Puri¢cation of soluble trypanosome gp83
Soluble gp83 was puri¢ed from glycosylphosphatidylinositol-phos-
pholipase C (GPI-PLC)-treated trypomastigote membrane fractions as
previously described [10]. Batches of trypomastigote membrane frac-
tions (each at 5U10310 cells) were treated with puri¢ed GPI-PLC
(Oxford GlycoSystems) in the presence of protease inhibitors [15]
followed by preparative isoelectric focusing (Bio-Rad) and Mono-Q
anion exchange chromatography using FPLC [10]. GPI-PLC actively
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cleaves proteins carrying GPI anchors, releasing a soluble protein
retaining the inositol glycan and diacylglycerol [16]. T. cruzi fractions
containing soluble GPI membrane-anchored proteins reacted posi-
tively by immunoblots with anti-cross-reacting determinant (CRD)
antibodies that recognize the membrane-soluble form of VSG of Try-
panosoma brucei (Oxford GlycoSystems) [17]. Fractions or puri¢ed
gp83 were analyzed by SDS^PAGE [18] followed by staining the
gels with silver stain, immunoblotting with anti-CRD antibodies
and mAb 4A4 [11], and testing for sialidase and trans-sialidase activ-
ities as described below. In addition, the radioiodinated puri¢ed solu-
ble gp83 trans-sialidase was deglycosylated with N-glycanase and its
mobility shift was analyzed by autoradiography [10].
2.4. Enzymatic activities
Trans-sialidase activity was determined in 10 Wl of puri¢ed gp83 in
20 mM HEPES pH 7.2, 1 mM sialylactose and 44 000^45 000 cpm of
the substrate (D-glucose-1-14C]lactose (speci¢c activity: 54 mCi/mmol,
Amersham). The reaction was incubated for 1 h at 37‡C, stopped and
passed through a QAE-Sephadex A-25 column [19]. Radioactive oli-
gosaccharides were eluted with 1 ml of 1 M ammonium formate and
the activity was expressed as eluted cpm. Sialidase activity was deter-
mined by measuring the £uorescence of 4-methyllumbelliferone re-
leased by the hydrolysis of 2P-(4-methylumbelliferyl) K-D-N-acetyl-
neuraminic acid [20]. Chromatographic fractions were incubated in
the presence of 1 mM 2P-(4-methylumbelliferyl)-K-D-N-acetylneura-
minic acid with constant agitation for 4 h at 25‡C. Puri¢ed sialidase
from Salmonella typhimurium (Oxford GlycoSystems) was used as
positive control. The reactions were stopped by addition of 100 mM
of Tris^HCl, pH 10, 100 mM NaCl2, 2 mM MgCl2 and £uorescence
was measured at 360 nm excitation and expressed in £uorescence
units. 4A-Fab, I-Fab, P-Fab or IP-Fab were preincubated with puri-
¢ed gp83 for 1 h at room temperature and tested for their ability to
inhibit sialidase and trans-sialidase activities.
2.5. Binding of gp83 trans-sialidase to host cells
Puri¢ed soluble gp83 trans-sialidase was radioiodinated in the pres-
ence of Iodogen at a speci¢c activity of 4.3U106 cpm/Wg protein as
described [20,21]. Binding of soluble [125I]gp83 trans-sialidase to rat
heart myoblast monolayers was carried out in Te£on microwell cham-
bers containing micromonolayers of heart myoblasts (104 cells/well)
[3]. Increasing concentrations of soluble [125I]gp83 trans-sialidase
(10 Wl) were added to myoblast monolayers in Hanks’ balanced salt
solution supplemented with bovine serum albumin (HBSS-BSA) and
10 Wl of HBSS-BSA alone or containing 100-fold excess unlabeled
soluble gp83 trans-sialidase to determine non-speci¢c binding. Each
point was done in triplicate. Cells were incubated at 4‡C for 2 h.
Unbound radioiodinated gp83 trans-sialidase was removed by three
washes with cold HBSS. Cell monolayers were lysed with 20 Wl of
2.5% SDS and the radioactivity was determined. Speci¢c binding was
determined [21] and binding data were analyzed using the Graphpad
Prism Software. Inhibition experiments were done using soluble
[125I]gp83 (40 ng/ml) in the presence of 4A4-Fab, I-Fab, P-Fab or
IP-Fab at 40 ng/ml. A control was also performed in the presence
of phosphate-bu¡ered saline (PBS) instead of Fab. Binding of bio-
tinylated gp83 trans-sialidase to Vero cell ¢broblast, baby hamster
kidney ¢broblast or mouse peritoneal macrophage micromonolayers
was performed as described [23]. Speci¢c binding was evaluated in the
presence of 100-fold unlabeled excess of gp83 or in the presence of
4A4-Fab or I-Fab. The reaction was developed with £uorescein-
labeled avidin [23].
2.6. Neutralization of T. cruzi binding and entry and mice infection
T. cruzi trypomastigote^cell interactions were performed using a
trypanosome:cell ratio of 10. The ability of 4A4-Fab or I-Fab to
inhibit the attachment of live trypomastigotes to 0.1% paraformalde-
hyde-¢xed rat heart myoblasts, Vero cell ¢broblasts and macrophages
was evaluated using microassays as described [3,22,24]. The ability of
Fig. 1. Puri¢ed soluble gp83 presents sialidase and trans-sialidase activities and 4A4-Fab do not inhibit these enzymatic activities, whereas
P-Fab do. A: Silver stain of puri¢ed gp83 (0.1 Wg) separated by SDS^PAGE. B: Mobility shift of [125I]gp83 treated with N-glycanase detected
by autoradiography. Untreated gp83 (lane 1) and treated gp83 (lane 2). C: Immunoblot of puri¢ed soluble gp83 probed with 4A4-Fab (lane 1),
I-Fab (lane 2), P-Fab (1ane 3) and IP-Fab (lane 4) developed by ECL. D: E¡ect of 4A4-Fab, I-Fab, P-Fab or IP-Fab on sialidase activity of
puri¢ed soluble gp83. Puri¢ed S. typhimurium sialidase was used as a positive control for sialidase activity. E: E¡ect of 4A4-Fab, I-Fab, P-Fab
or IP-Fab on trans-sialidase activity of puri¢ed soluble gp83. Each column represents the mean of triplicate determinations þ S.D. Di¡erences
between * and the rest, P6 0.01.
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these Fab to inhibit trypanosome internalization into myoblasts,
¢broblasts and macrophages was performed as described [3,22]. The
ability of 4A4-Fab to neutralize T. cruzi infection in mice was eval-
uated as follows. Either 4A4-Fab or I-Fab (20 Wg in PBS) were ad-
ministered i.v. into 4-week-old BALB/c female mice (n = 10) 2 h before
i.v. challenge with 2U103 blood trypomastigotes and mice were given
three consecutive i.p. injections of either 4A4-Fab or I-Fab (20 Wg) for
the next 3 days. The number of trypomastigotes in the blood was
monitored in 5 Wl tail blood [25].
2.7. Presentation of results and statistical analysis
Results in this work were obtained from triplicate values and rep-
resent three independent experiments with identical protocols. Results
are expressed as the mean þ 1 S.D. Di¡erences were considered to be
statistically signi¢cant if P6 0.05 as determined by Student’s t-test or
by the Mann^Whitney U-test for the in vivo experiments.
3. Results
3.1. The surface T. cruzi gp83 is a trans-sialidase that binds to
myoblasts, ¢broblasts and macrophages in a
ligand^receptor interaction manner and this binding is
neutralized by 4A4-Fab
The puri¢ed soluble surface gp83 from T. cruzi trypomas-
tigote membranes treated with GPI-PLC (Fig. 1A) presents
N-linked oligosaccharides (Fig. 1B) and sialidase and trans-
sialidase activities (Fig. 1D,E). Uncleaved mAb 4A4 speci¢c
for gp83 was previously shown to inhibit T. cruzi trypomas-
tigote binding to myoblasts [11]. Both the mAb 4A4 and poly-
clonal antibodies speci¢c for gp83 are able to immunopreci-
pitate the soluble gp83 (results not shown). 4A4-Fab
recognize the gp83 by immunoblots (Fig. 1C) and do not
inhibit either the sialidase or trans-sialidase activities of
gp83 (Fig. 1D,E). However, P-Fab, which also recognize the
puri¢ed soluble gp83 (Fig. 1C), neutralize both sialidase and
trans-sialidase activities, whereas IP-Fab do not (Fig. 1D,E).
These results indicate that 4A4-Fab do not recognize the sia-
lidase or trans-sialidase active site of the gp83 molecule. Pu-
ri¢ed soluble radioiodinated gp83 trans-sialidase (Fig. 2A)
binds to heart myoblasts in a ligand^receptor interaction
manner with a Kd of 8 nM (Fig. 2B). Myoblasts display a
single class of receptors for the gp83 trans-sialidase, present at
4U104 per myoblast (Fig. 2B). Binding of [125I]gp83 trans-
sialidase to myoblasts is abolished in the presence of 4A4-
Fab, but not in the presence of I-Fab (Fig. 2C). Biotinylated
gp83 trans-sialidase also binds to Vero cell ¢broblasts and
macrophages and this binding is inhibited by an excess of
either unlabeled gp83 or 4A4-Fab (Fig. 2D). I-Fab do not
inhibit these interactions (results not shown). Similar results
were observed when baby hamster kidney ¢broblasts were
used (results not shown). These results indicate that the
gp83 trans-sialidase binds to myoblasts, ¢broblasts and mac-
rophages in a ligand^receptor interaction manner and that
these interactions do not involve the enzymatic active site of
the gp83.
Fig. 2. Labeled puri¢ed soluble gp8 trans-sialidase binds to myoblasts, ¢broblasts, and macrophages in a ligand^receptor interaction manner
and these interactions are inhibited by 4A4-Fab. A: Autoradiogram of the radioiodinated puri¢ed soluble gp83 trans-sialidase subjected to
SDS^PAGE used for binding studies. B: Binding of [125I]gp83 trans-sialidase to heart myoblasts. Inset: Scatchard analysis of the binding data.
C: Inhibition of [125I]gp83 trans-sialidase binding to myoblasts by 4A4-Fab. D: Binding of biotinylated soluble gp83 trans-sialidase to Vero cell
¢broblasts and macrophages developed by £uorescein-labeled avidin and inhibition of this binding by excess unlabeled gp83 or 4A4-Fab. Each
column in C represents the mean of triplicate determinations þ S.D. Di¡erences between * and the rest, P6 0.01.
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3.2. 4A4-Fab block the trypomastigotes from attaching to and
entering myoblasts, ¢broblasts and macrophages and
neutralizes T. cruzi infection in BALB/c mice
We reasoned that if trypomastigotes use gp83 trans-siali-
dase to bind to heart myoblasts, ¢broblasts and macrophages,
then 4A4-Fab, which block the binding of this molecule to
these cells (Fig. 2), should inhibit the attachment and internal-
ization of trypomastigotes into host cells. Indeed, 4A4-Fab
e¡ectively blocked trypomastigote attachment to heart myo-
blasts, Vero cell ¢broblasts and macrophages in a concentra-
tion-dependent manner (Fig. 3A). A signi¢cant reduction in
trypanosome entry these cells was detected at 4 h (Fig. 3B).
4A4-Fab e¡ectively inhibited trypomastigote binding and in-
ternalization into mammalian cells at nanogram amounts,
whereas I-Fab failed to inhibit binding and internalization
of trypanosomes; values obtained with I-Fab were similar to
PBS controls (data not shown). 4A4-Fab neutralize T. cruzi
trypomastigote infection in BALB/c mice (Fig. 4). I.v. injec-
tion of 4A4-Fab into BALB/c mice 2 h before i.v. challenge
with a lethal dose of blood trypomastigotes followed by three
i.p. doses of 4A4-Fab dramatically reduced parasitemia com-
pared to control mice receiving I-Fab (Fig. 4A). After 27
days, the mortality of mice receiving I-Fab was 100%, whereas
no mortality was observed in the group of mice receiving 4A4-
Fig. 3. 4A4-Fab neutralize T. cruzi trypomastigote binding to myoblasts, ¢broblasts and macrophages and prevent parasite entry into these
cells. A: Binding of trypomastigotes to heart myoblasts, Vero cell ¢broblasts and macrophage monolayers after 2 h of interaction. B: Internal-
ization of trypomastigotes into myoblasts, Vero cell ¢broblasts and macrophages after 4 h. Each bar represents the mean of triplicate determi-
nations þ S.D. Di¡erences in parasite internalization between test and control, P6 0.05.
 
Fig. 4. Injection of 4A4-Fab into BALB/c mice neutralizes the infectivity of T. cruzi trypomastigotes. A: Levels of blood trypomastigotes in
mice injected with either 4A4-Fab or I-Fab and infected with T. cruzi blood trypomastigotes as described in Section 2. B: Mortality of T. cru-
zi-infected BALB/c mice receiving either 4A4-Fab or I-Fab. Each column represents the mean of parasitemia þ S.D. Di¡erences in parasitemia
between test and control, P6 0.05.
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Fab (Fig. 4B). At the termination of the experiment (118
days) no mortality had been observed in these mice. Parasite-
mia levels and mortality with I-Fab were similar to PBS con-
trols (data not shown). Taken together these results indicate
that 4A4-Fab strongly neutralize the infectivity of T. cruzi in
vitro and in vivo by blocking the surface gp83 trans-sialidase
ligand of invasive forms of this organism.
4. Discussion
These results indicate for the ¢rst time that T. cruzi trypo-
mastigotes use the surface gp83 trans-sialidase to bind to host
cell receptors in order to mediate attachment and initiate in-
fection in vitro and in vivo. Binding of gp83 trans-sialidase to
phagocytic and non-phagocytic cells to promote entry in the
host appears not to require the enzyme active site of gp83
trans-sialidase, since 4A4-Fab, which abolish binding of la-
beled gp83 trans-sialidase to mammalian cells and neutralize
in vitro and in vivo infection, do not a¡ect the sialidase and
trans-sialidase activities that the gp83 bears. Furthermore,
these results also indicate that the epitope recognized by the
mAb 4A4 on the gp83 trans-sialidase of trypomastigotes is
required for trypanosome binding to phagocytic and non-
phagocytic cells to initiate in vitro and in vivo infection.
To our knowledge this is the ¢rst report to determine the
number of receptors on a cell for a soluble surface molecule of
invasive T. cruzi trypomastigotes and the Kd of this interac-
tion. Heart cells are a major target for T. cruzi and infection
of these cells is involved in cardiac arrest followed by death
[1]. Elucidation of the molecular interactions between T. cruzi
molecules and their receptors on heart cells may be important
not only to understand how T. cruzi enters heart cells to alter
their cardiophysiology, but also to the development of molec-
ular means of intervention against Chagas’ heart disease. Cur-
rent studies in our laboratory indicate that the T. cruzi gp83
trans-sialidase interacts with a p74 expressed on the surface of
heart cells [23] and on other cells that T. cruzi infects and that
p74 functions as a receptor for T. cruzi and for the gp83 trans-
sialidase [26].
The fact that this molecule is also expressed in other strains
of T. cruzi [5] and that our ¢ndings in this report indicate that
the gp83 trans-sialidase binds receptors on cells other than
heart cells that are able to be infected by T. cruzi such as
macrophages and ¢broblasts, strongly suggests that the gp83
trans-sialidase of T. cruzi is a universal ligand that this organ-
ism uses to bind to and enter phagocytic and non-phagocytic
cells to initiate infection in the body. These ¢ndings raise the
possibility that invasive trypomastigotes might up- and down-
regulate their infectivity to mammalian cells by modulating
expression and secretion of the gp83 trans-sialidase. In fact,
recent reports have shown that secretion of gp83 trans-siali-
dase by trypomastigotes increases parasite entry in human
macrophages by activating a protein kinase C (PKC)-depen-
dent mitogen-associated protein (MAP) kinase pathway in
these host cells [27,28].
Fab fragments of mAb 4A4 speci¢c for gp83 trans-sialidase
inhibit gp83 trans-sialidase binding to myoblasts, ¢broblasts
and macrophages, block trypanosomes from attaching to and
entering myoblasts, ¢broblasts and macrophages and neutral-
ize T. cruzi infection in BALB/c mice. These observations also
strongly support the notion that gp83 trans-sialidase is a li-
gand used by T. cruzi to attach to phagocytic and non-phag-
ocytic cells to promote entry and initiate in vitro and in vivo
infection. Since 4A4-Fab strongly but not completely neutral-
ize T. cruzi infectivity in vitro and in vivo, we do not exclude
the possibility that this organism may use alternative mecha-
nisms to invade host cells. A very recent report has implicated
the 85 kDa protein in host cell invasion in vitro [29]. While
both the gp83 and the 85 kDa protein cover part of the sur-
face of trypomastigotes and play roles in infection, the gp83
ligand binds to host cell receptors on mammalian cells to up-
regulate trypomastigote entry by activating host tyrosine ki-
nases in a PKC-dependent MAP kinase pathway [27,28]. The
gp83 is the ¢rst T. cruzi ligand described that triggers host cell
receptors to activate host cell signal transduction events that
are necessary and essential for trypanosome entry [27,28]. The
gp83 ligand binds to a p74 host cell receptor [23,26] expressed
on the membrane of all non-phagocytic and phagocytic cells
that T. cruzi can infect, whereas peptide j derived from 85
kDa protein appears to restrict its interaction with a 45
kDa cytokeratin of epithelial cells [29]. Moreover, the a⁄nity
of the gp83 ligand for host cell receptors is seven times higher
than the synthetic peptide j. T. cruzi surface molecules that
bind to host cell receptors during invasion may be of interest
for developing vaccines and receptor blocking therapies. In
summary, we identi¢ed a ligand on invasive forms of T. cruzi
that is used by this organism to adhere to phagocytic and
non-phagocytic cells to initiate in vitro and in vivo infection.
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